---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-090482"
form_type: "8-K"
ticker: "ADIL"
cik: "0001513525"
company_name: "ADIAL PHARMACEUTICALS, INC."
filed_at: "2026-08-17T11:17:57+00:00"
generated_at: "2026-08-17T11:20:29.364141+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Adial reports Q2 net loss of $52M; closes Azora acquisition and $32M financing

## Summary
- Net loss of $52.0M ($11.25/share) vs $2.0M loss ($4.61/share) in Q2 2025; includes $46.2M non-cash IPR&D charge.
- Completed acquisition of Azora Therapeutics, adding AT177, an oral colon-targeted AhR agonist for ulcerative colitis; IND planned for H1 2027.
- Closed initial $32M tranche (incl. $5.5M note conversion) of up to $64M private placement; cash $28.7M at June 30 vs $4.6M at March 31.
- G&A expenses rose to $5.4M from $1.2M YoY on merger costs and severance; R&D fell to $440K from $732K.
- Cash runway into H2 2027; stockholders' deficit of $38.4M with $38.5M Series A preferred pending conversion approval.

## SEC filing metadata
- accession: 0001213900-26-090482
- form_type: 8-K
- ticker: ADIL
- cik: 0001513525
- company_name: ADIAL PHARMACEUTICALS, INC.
- filed_at: 2026-08-17T11:17:57+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1513525/000121390026090482/0001213900-26-090482-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1513525/000121390026090482/ea0301966-8k_adial.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-090482
- JSON: https://secwatch.observer/filing/0001213900-26-090482.json
- Plain text: https://secwatch.observer/filing/0001213900-26-090482.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.